Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Orum Therapeutics Appoints Jae Won Kim Chief Financial Officer

Orum Therapeutics, a global biotech company pioneering the development technologies for precision delivery of targeted protein degraders to treat cancer, today announced the appointment of Jae Won Kim as Chief Financial Officer.

“We are excited to welcome Jae Won to the Orum team,” said Sung Joo Lee, Ph.D., Founder and CEO of Orum Therapeutics. "Jae Won brings deep expertise in healthcare investment banking with a broad range of finance and deal experience. Her appointment comes at an important juncture for the company, and she will play a pivotal role in driving sustainable long-term growth, supporting the company to ascend to the next level.”

“I’m impressed by Orum’s differentiated platform that combines targeted protein degradation with the precision of antibody drug conjugate technology,” said Ms. Kim. “Orum has great potential for developing innovative, first-in-class targeted protein degradation therapeutics that can be applied to many different diseases driven by targets that are currently considered undruggable.”

Prior to joining Orum, Jae Won Kim served as a Director on the Citi Healthcare Investment Banking team based in New York. She spent more than 10 years in the financial industry, where she advised healthcare companies on strategic transactions and led various financings. She completed a joint JD-MBA program at Northwestern University and earned a BA in English Literature and Business Administration from Korea University. She is an attorney-at-law in the state of New York.

About Orum Therapeutics

Orum Therapeutics is pioneering the development of technologies for precision delivery of targeted protein degraders for the treatment of cancer. The company’s neoDegraders are novel, proprietary payloads for targeted protein degradation and its Antibody neoDegrader Conjugate (AnDC) platform generates first-in-class antibody drug conjugates. The first therapeutic candidates from the AnDC platform are in development for the treatment of solid tumors and hematologic cancers. Orum is located in Cambridge, Massachusetts, U.S., and Daejeon, South Korea. For more information, visit www.orumrx.com.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.